DE2611976C2 - Verwendung von L-Pyroglutamyl-L-histidyl-L-prolinamid oder dessen physiologisch verträglichen Salzen zur Behandlung von Zuständen verminderten Bewußtsein - Google Patents
Verwendung von L-Pyroglutamyl-L-histidyl-L-prolinamid oder dessen physiologisch verträglichen Salzen zur Behandlung von Zuständen verminderten BewußtseinInfo
- Publication number
- DE2611976C2 DE2611976C2 DE2611976A DE2611976A DE2611976C2 DE 2611976 C2 DE2611976 C2 DE 2611976C2 DE 2611976 A DE2611976 A DE 2611976A DE 2611976 A DE2611976 A DE 2611976A DE 2611976 C2 DE2611976 C2 DE 2611976C2
- Authority
- DE
- Germany
- Prior art keywords
- trh
- consciousness
- treatment
- patient
- pyroglutamyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 title claims description 42
- 238000011282 treatment Methods 0.000 title claims description 17
- 150000003839 salts Chemical class 0.000 title claims description 10
- 229940095064 tartrate Drugs 0.000 claims description 15
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 14
- 208000014674 injury Diseases 0.000 claims description 7
- 230000008733 trauma Effects 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 230000006872 improvement Effects 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 5
- 208000003443 Unconsciousness Diseases 0.000 description 4
- 230000006931 brain damage Effects 0.000 description 4
- 231100000874 brain damage Toxicity 0.000 description 4
- 208000029028 brain injury Diseases 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 208000006888 Agnosia Diseases 0.000 description 3
- 241001047040 Agnosia Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 206010010071 Coma Diseases 0.000 description 2
- 206010015727 Extensor plantar response Diseases 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- -1 acid addition salts Chemical class 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 238000007428 craniotomy Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 206010052346 Brain contusion Diseases 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000009516 brain contusion Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- SIXLXDIJGIWWFU-UHFFFAOYSA-N pyritinol Chemical compound OCC1=C(O)C(C)=NC=C1CSSCC1=CN=C(C)C(O)=C1CO SIXLXDIJGIWWFU-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/066—TRH, thyroliberin, thyrotropin releasing hormone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1365275 | 1975-04-03 | ||
| GB4855775 | 1975-11-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2611976A1 DE2611976A1 (de) | 1976-10-14 |
| DE2611976C2 true DE2611976C2 (de) | 1987-01-15 |
Family
ID=26249900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2611976A Expired DE2611976C2 (de) | 1975-04-03 | 1976-03-20 | Verwendung von L-Pyroglutamyl-L-histidyl-L-prolinamid oder dessen physiologisch verträglichen Salzen zur Behandlung von Zuständen verminderten Bewußtsein |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US4059692A (show.php) |
| JP (1) | JPS51118841A (show.php) |
| DE (1) | DE2611976C2 (show.php) |
| FR (1) | FR2313075A1 (show.php) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5920647B2 (ja) * | 1976-10-01 | 1984-05-15 | 武田薬品工業株式会社 | 注射剤 |
| JPS6047244B2 (ja) * | 1977-01-05 | 1985-10-21 | 武田薬品工業株式会社 | 薬剤 |
| US4426378A (en) | 1981-04-09 | 1984-01-17 | The United States Of America As Represented By The Secretary Of The Army | Thyrotropin releasing hormone in therapy of shock and as a central nervous system stimulant |
| JPS57188526A (en) * | 1981-05-14 | 1982-11-19 | Takeda Chem Ind Ltd | Peptide-containing pharmaceutical preparation |
| US4493828A (en) * | 1982-07-26 | 1985-01-15 | Merck & Co., Inc. | Use of thyrotropin releasing hormone and related peptides as poultry growth promotants |
| GB2171101A (en) * | 1985-02-20 | 1986-08-20 | Tanabe Seiyaku Co | Peptide and processes for preparation of the same |
| US5482706A (en) * | 1992-04-17 | 1996-01-09 | Takeda Chemical Industries, Ltd. | Transmucosal therapeutic composition |
| US7462595B2 (en) * | 2004-09-17 | 2008-12-09 | Prange Jr Arthur Jergen | Methods for treating cancer-related fatigue |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3737549A (en) * | 1972-03-20 | 1973-06-05 | Abbott Lab | Method of treating depression |
| AU5873073A (en) * | 1972-08-14 | 1975-02-06 | Abbott Laboratories | Method for controlling fertility |
| US3860570A (en) * | 1973-02-26 | 1975-01-14 | Abbott Lab | Tripeptide intermediate for making trh |
| US3873709A (en) * | 1974-02-19 | 1975-03-25 | Abbott Lab | Method of treating psychosis |
| US3932623A (en) * | 1974-06-18 | 1976-01-13 | Wilson Ian C | Method of treating schizophrenia |
-
1976
- 1976-03-16 JP JP51029025A patent/JPS51118841A/ja active Granted
- 1976-03-19 FR FR7608123A patent/FR2313075A1/fr active Granted
- 1976-03-20 DE DE2611976A patent/DE2611976C2/de not_active Expired
- 1976-03-22 US US05/669,455 patent/US4059692A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| FR2313075B1 (show.php) | 1979-10-12 |
| US4059692A (en) | 1977-11-22 |
| JPS5633368B2 (show.php) | 1981-08-03 |
| FR2313075A1 (fr) | 1976-12-31 |
| JPS51118841A (en) | 1976-10-19 |
| DE2611976A1 (de) | 1976-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69621603T2 (de) | Behandlung von cerebraler ischämie und cerebralen verletzungen mit nervenschutzmitteln | |
| DE69632743T2 (de) | Verfahren zur regulierung des vagaltonus | |
| JPS58121213A (ja) | アルツハイマ−病治療剤 | |
| DE3235093A1 (de) | Antiparkinsonmittel | |
| EP0185210B1 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten | |
| EP1103256A1 (de) | Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom | |
| DE60111025T2 (de) | Verwendung von Topiramat zur Behandlung und Diagnostizierung von Atemstörungen während des Schlafens und Mittel zur Durchführung der Behandlung und Diagnose | |
| DE69821498T2 (de) | Verwendung von amifostin | |
| DE69201660T2 (de) | Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma. | |
| DE2611976C2 (de) | Verwendung von L-Pyroglutamyl-L-histidyl-L-prolinamid oder dessen physiologisch verträglichen Salzen zur Behandlung von Zuständen verminderten Bewußtsein | |
| DE69413090T2 (de) | Verwendung von 5-Amino-Phthaloylhydrazid als antihypoxisches und defensives Mittel | |
| Guerrero-Figueroa et al. | Electrographic and behavioral effects of diazepam during alcohol withdrawal stage in cats | |
| EP0585896B1 (de) | Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks | |
| DE69110615T2 (de) | Verwendung von Aminosäuren zum Schutz von ischemischem Herzgewebe und dessen metabolischer Wiederherstellung. | |
| EP0345247A2 (de) | Verwendung von monosubstituierten selenorganischen Verbindungen zur Herstellung eines Arzneimittels sowie daraus hergestelltes Arzneimittel und Verfahren zu seiner Herstellung | |
| DE69529819T2 (de) | Neue kombination eines betablockers mit einem lokalanästhetikum | |
| EP0132595B1 (de) | Tokolytisches Mittel | |
| EP1001756B1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| DE69332055T2 (de) | Zusammensetzung von Argatroban zur Verwendung in Ophthalmologie | |
| DE3116859A1 (de) | Therapeutische zubereitungen fuer die behandlung einer tardiven dyskinesie | |
| DE3234061C2 (show.php) | ||
| DE2131679A1 (de) | 3,4,5-Trimethoxybenzamidocarbonsaeure und ihre Salze sowie Arzneipraeparate | |
| DE69631597T2 (de) | Kombination aus einem beta rezeptorblocker und einem opioid | |
| EP0845264A1 (de) | Teil- oder Vollextrakt aus nicht fermentierter Camellia sinensis L. | |
| EP0913153A1 (de) | Verwendung von Thiaminen zur Herstellung eines Arzneimittels zur Prophylaxe und zur Therapie der diabetischen Retinopathie und der diabetischen Nephropathie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |